Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
R-Pharm US is hiring 10 roles related to this product
Company
R-Pharm US
NJ - Princeton
APREPITANT (aprepitant) by R-Pharm US is neurokinin 1 antagonists [moa]. Approved for combination with other antiemetic agents, older for prevention of: acute, delayed nausea and 7 more indications. First approved in 2017.
Drug data last refreshed 20h ago
Neurokinin 1 Antagonists
Substance P/Neurokinin-1 Receptor Antagonist
Worked on APREPITANT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moR-Pharm US is hiring 10 roles related to this product